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Abstract
Background: Hyperparathyroidism is a disease characterized by excessive secretion of parathyroid hormone, the
hormone responsible for calcium and phosphate homeostasis in the body. It can be of three types: primary, secondary,
or tertiary. It is essential to bear in mind that in any one patient more than one type of hyperparathyroidism may be
found, which may create perplexity regarding the etiology of the case. Hyperparathyroidism can become apparent
early in its course when a patient presents with symptoms of abdominal pain, recurrent renal calculi, repeated
fractures, or behavior changes. It is generally accepted that bone involvement is a late manifestation of primary
hyperparathyroidism. It is imperative to consider that some patients, such as our patient described in this report, may
be previously asymptomatic clinically and on the basis of laboratory findings and present with only late skeletal
manifestations. Brown tumors are one of the mimickers of lytic lesions of the jaw and need to be ruled out early in the
course of management. Researchers in several studies published in high-impact journals have recommended the use
of high-dose vitamin D as safe in patients with primary hyperparathyroidism without the risk of raising calcium levels
significantly. In our patient, we observed considerable hypercalcemia after high-dose vitamin D therapy, and we
propose exercising discretion with the use of high-dose therapies.
Case presentation: We report a case of a 21-year-old Arab woman with a brown tumor who presented with
hypocalcaemia. She presented with a mixed picture of primary hyperparathyroidism and severe vitamin D deficiency.
Conclusions: Brown tumors, although thought to be a forgotten entity with the advent of early screening for
hypercalcemia, is still prevalent, as a handful of patients may present late in the disease course with no early markers,
such as in our patient. We emphasize using a holistic approach for early diagnosis and adopting a restricted attitude to
treating these benign entities, especially in the context of cosmesis for sensitive locations such as the face. In addition,
we express caution in using daily supplementation with a high vitamin D dose to improve vitamin D status and
decrease parathyroid hormone.
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Background
Primary hyperparathyroidism (PHPT) is one of the most
common endocrine disorders encountered in endocrin-
ology practice today. The frequencies of various parathy-
roid lesions underlying the hyperfunction are adenoma
(80–95 %), primary hyperplasia (5–10 %), and parathy-
roid carcinoma (1 %) [1]. PHPT is a disease of adulthood
seen mostly in those older than 50 years of age, and it is
more common in women [2]. Eighty percent of patients
are identified on the basis of an incidental discovery of
hypercalcemia. In severe and late stages of hyperpara-
thyroidism, skeletal changes can be observed. These
changes include an increased number of osteoclasts,
which erode bone matrix and increase bone resorption.
This in turn causes increased osteoblastic activity, which
results in new bone formation. The bone loss predis-
poses individuals to microfractures and hemorrhages,
which result in an influx of macrophages and increased
fibrous tissue, creating a mass of reactive tissue known
as osteitis fibrosa cystica. It is also known as brown
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tumor, the color of which can be attributed to the in-
creased hemorrhage and hemosiderin deposition.
In recent years, osteitis fibrosa cystica has become very
rare in hyperparathyroidism, owing to earlier detection
of the disease. The common locations for the brown
tumor are the ends of long bones, the pelvis, and ribs.
Facial involvement is rare and, when present, usually in-
volves the mandible [3].
In this article, we report a case of brown tumor of the
mandible, maxilla, and patella as a first presentation of
PHPT masked by severe vitamin D deficiency in a pa-
tient with a previous history of only repeated fractures.
We discuss the patient’s unusual age at presentation; the
uncommon location of the tumor; its symptomless late
presentation; and the use of a less aggressive, conserva-
tive, multidisciplinary approach to the treatment of the
tumor. This case also emphasizes the need to consider
PHPT early in the differential diagnosis of tumorous le-
sions of the jaw. The patient was followed for 3 years
postoperatively to assess the effectiveness of surgery
alongside adjunctive treatment in maintaining low para-
thyroid hormone (PTH) levels and regression of the
brown tumor lesions, as well as to assess the patient’s
satisfaction in the long term.
Case presentation
A 21-year-old, unmarried Arab woman with no known
comorbidities presented with a massive swelling on the
right side of her face that had been slowly increasing in
size for the past 3 years, as well as with difficulty in
bending her left knee. The swelling was large enough to
cause trismus, and the patient was unable to open her
right eye fully. She had no associated pain, bleeding, or
superficial ulceration of the mass. The history taking for
her presenting illness revealed multiple admissions for
recurrent fractures. She had experienced no associated
headaches, psychiatric manifestations, renal stones, or
abdominal pain. She had no history of weight loss, fever,
or night sweats. She had a negative family history for
any tumors or disorders of calcium homeostasis. She
also displayed psychological distress and concern re-
garding the impact of the mass on her appearance.
Her social functioning and activities of daily living
were markedly affected.
An extraoral examination showed a nontender hard
swelling on the right side of the mandible that was caus-
ing facial deformity. An intraoral examination revealed a
nontender firm swelling that was expanding the buccal
mucosa and lingual mandibular plates, obliterating the
buccal sulcus, and extending from the right premolars
to the ascending ramus. The patient had a displaced,
partially impacted tooth 18, mobile teeth 36 and 37,
and nontender swelling of the left maxillary region
with obliteration of the upper left buccal sulcus. A
panoramic x-ray of the patient’s teeth showed a right
mandibular swelling and an impacted left lower wis-
dom tooth (Fig. 1).
The patient’s thyroid examination result was normal.
She had no associated lymphadenopathy or skeletal de-
formities. An examination of the lower extremities
showed that the left knee had mild limitation of move-
ment. The patient had no tenderness, erythema, or
swelling of the knee joint or proximal leg on the left
side. An examination of the patient’s right lower extrem-
ity was unremarkable.
She initially presented as an outpatient to the maxillo-
facial surgery department. The mass was suspected to be
malignant, and a biopsy of the lesion was taken. The bi-
opsy report showed a giant cell lesion and was referred
to the endocrinology department to rule out metabolic
bone disease. Her lesion was identified as a brown tumor
of hyperparathyroidism, and laboratory investigations
were done (Table 1).
The initial impression was of secondary hyperparathyr-
oidism due to severe vitamin D deficiency, although the
patient’s PTH level was remarkably high. The other sus-
picion was of PHPT masked by vitamin D deficiency.
Maxillofacial computed tomography (CT) with con-
trast enhancement showed multiple maxillofacial expan-
sile lesions with ground-glass ossification. The largest
lesion within the right mandible involved the body and
b
a
Fig. 1 Panoramic x-ray of the patient’s teeth showing right mandibular
swelling and an impacted left lower wisdom tooth. a Preoperative
x-ray. b Postoperative intralesional steroid injection and removal of the
left lower wisdom tooth
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ramus. It measured 6.4 × 4.1 cm. The largest lesion in
the left maxilla involved the alveolar edge and measured
3.6 × 3.3 cm. No lymphadenopathy was seen (Fig. 2a).
A positron emission tomography CT scan showed
multiple hypermetabolic, expansile, bony lytic lesions in
the right mandible, left maxillary sinus, left mandible,
and manubrum sterni (Fig. 3).
Magnetic resonance imaging (MRI) of the left lower
extremity showed a heterogeneous, solid, and soft tissue
mass involving the proximal epimetaphysis of the tibia
and extending to the subarticular cortex. The mass was
approximately 4.8 × 4.2 cm in size (Fig. 4a).
The patient was started on vitamin D 50,000 U by
mouth weekly for 6 weeks. Her PTH levels decreased
after 4 months on vitamin D therapy, but her calcium
levels rose significantly (Table 1). The vitamin D dose
was reduced because of fear of hypercalcemia, and the
patient was kept on 5000 U weekly thereafter. An ultra-
sound scan of the parathyroid gland was done at the
time, which showed a right lower lobe parathyroid solid
Table 1 Time line of the patient’s serial laboratory investigations
Investigations Normal values Initial values After 4 months of
vitamin D therapy
Postsurgery 2-month
follow-up
3-year
follow-up
PTH, pg/ml 5–68.3 1652.7 564.6 154.6 222 103.3
Calcium, mmol/L 2.22–2.64 2.16 3.02 2.23 2.35 2.36
Phosphorous, mmol/L 0.70–1.50 0.71 0.94 0.81 1.22 0.93
Alkaline phosphatase, U/L 54–144 875 444 363 336 83
25(OH)D, ng/ml 40–100 5.84 18.3 15.2 29.5 24.8
Serum creatinine, U/L 10–70 41.0 35.0 52.0 51.0 42.0
Estimated glomerular filtration rate, ml/minute/1.73 m2 >90 144.28 150.93 132.5 133.35 139.21
PTH parathyroid hormone
a b
c
Fig. 2 Maxillofacial computed tomographic scans with contrast enhancement showing multiple expansile lesions with ossification. The largest
lesion can be seen within the body and ramus of the mandible. a Preoperative scan. b Scan obtained 5 months postoperatively demonstrating
increased ossification of the lesion. c Scan obtained 1.5 years postoperatively showing reduction in the size of the lesion
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nodule. A technetium Tc-99 m sestamibi parathyroid
study showed increased activity in the soft tissue mass,
approximately 13.0 mm in size and lying behind the
lower part of right thyroid lobe, suggestive of parathy-
roid adenoma (Fig. 5).
She was referred to surgical oncology and underwent
right lower parathyroid adenoma excision. Her PTH
levels improved significantly after surgery (Table 1).
Postoperatively, she had a brief episode of hypocalcemia
(1.97 mmol/L), and she was started on calcium carbon-
ate 1200-mg tablets twice daily for 2 weeks. She was re-
ceived maxillofacial follow-up for intralesional steroid
60-mg methylprednisolone depot injection as well as
endocrinological follow-up for vitamin D therapy. She
was followed with frequent laboratory and radiological
investigations for the next 3 years, through the reporting
of this case, and the masses have shrunk in size.
Maxillofacial contrast-enhanced CT performed 5months
after resection of the parathyroid adenoma showed lesions
with more ossification, which could be a sign of healing.
The largest right mandibular lesion was stable in size, but
the left maxillary mass was reduced in size to 3 × 2.5 cm
(compared with 3.6 × 3.3 cm previously) (Fig. 2b). CT per-
formed 1.5 years postsurgery showed reduction in size of
the right mandibular lesion to 5.5 × 4.0 cm (compared
with 6.4 × 4.1 cm previously), and the maxillary lesion was
further reduced to 2.3 × 2.2 cm (Fig. 2c).
MRI of the left knee with contrast enhancement
performed 6 months postsurgery showed a mild de-
crease in size since the previous study, with increased
sclerosis of the solid component (Fig. 4b). MRI of the
left knee performed 2.5 years postsurgery showed further
reduction in the size of the lesion from the previous
study (Fig. 4c).
Overall, the patient showed serological, radiological,
clinical, and psychological improvement from her initial
condition. Although we were not able to retrieve an
initial photograph for comparison, we took a picture
of the mass after its marked reduction 1.5 years
postoperatively.
Discussion
Brown tumors, albeit more commonly found in PHPT,
can also be seen with secondary causes such as vitamin
D deficiency or renal disease. Our patient demonstrated
overlap between PHPT caused by parathyroid adenoma
and vitamin D deficiency secondary to hyperparathyroid-
ism. Before the 1970s, PHPT was a disease characterized
by recurrent kidney stones, brown tumors, neuromuscu-
lar dysfunction, and symptomatic hypercalcemia [4].
Today, it can be diagnosed in the early and asymptom-
atic period because of advances in blood analysis and a
growing awareness of this disease [5]. However, the case
of our patient highlights the significance of keeping
brown tumors high on the list in the differential diagno-
sis of a patient presenting with a bony mass, even if the
patient shows no signs of hyperparathyroidism and the
patient’s calcium levels are normal or subnormal.
The name tumor is a misnomer because the lesion,
although invasive in some instances, does not have a
neoplastic potential and should be differentiated from
true giant cell tumors of bone [6]. Brown tumors are
very similar to giant cell tumors, but in the context
of hyperparathyroidism they are considered reparative
granulomas [7].
When a patient—especially a middle-aged patient—
presents with unexplained lytic bone lesions or patho-
logical fractures, surgeons, endocrinologists, and especially
radiologists should be reminded of this unusual presenta-
tion of PHPT to avoid unnecessary surgical removal [8].
Radiographic findings can mimic bone malignancy, while
Fig. 3 Positron emission tomography computed tomographic scan
showing multiple hypermetabolic, expansile, bony lytic lesions in the
right mandible, left maxillary sinus, left mandible, and
manubrum sterni
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the synchronous involvement of multiple skeletal seg-
ments can be interpreted as diffuse metastatic disease [9].
There are very few case reports in the literature
describing Brown tumor localized in the maxillary and
facial regions in PHPT [10]. In the case of a lesion in the
lytic region of the jaw bones, the most likely diagnoses
would include hyperparathyroidism-jaw tumor syndrome,
odontogenic cysts and tumors (radicular cyst, lateral peri-
odontal cyst, and ameloblastoma), infectious diseases
(bone abscess, localized osteomyelitis), metabolic bone
disease hyperparathyroidism, metastasis from a known or
an unknown primary site (lung, breast, kidney, prostate),
and primary bone tumors and cysts (simple bone cyst, eo-
sinophilic granuloma, giant cell lesions, odontogenic kera-
tocyst, myxoma, and odontogenic fibroma) [7].
Total or subtotal parathyroidectomy is the gold stand-
ard for the treatment of PHPT [11], which we performed
in our patient. The following is a summary of the
National Institutes of Health guidelines [12] for parathy-
roidectomy in asymptomatic patients:
1. Serum calcium at least 1 mg/dl above the upper
limit of normal
2. Creatinine clearance reduced by more than 30 % as
compared with age-matched controls
3. T-score less than or equal to −2.5 or fragility fracture
4. Age younger than 50 years
As reviewed in Table 1, although postoperatively our
patient’s PTH levels reached normal limits, it is import-
ant to closely follow these patients for recurrence and
fluctuations in hormone levels. In addition, as an adjunct
to surgery, we used pharmacotherapy to maintain our
patient’s serum hormone levels and reduce her brown
tumor further to negate the need for further surgical
procedures. She is being maintained on vitamin D3 5000
U/week, along with intralesional steroids.
We reviewed three studies published in high-impact
journals in which authors advocated the use of high vita-
min D doses safely in patients with PHPT. In one study
done in 2014, authors stated that vitamin D replacement
in mild PHPT with coexistent vitamin D deficiency
reduces parathyroid levels significantly without signs of
hypercalcemia or hypercalciuria [13, 14]. Another retro-
spective study demonstrated that 25(OH)D increased sig-
nificantly (P < 0.0001) from a baseline of 14.65 ± 6.57 ng/
a
b
c
Fig. 4 Magnetic resonance imagining of the patient’s left knee
showing a heterogeneous, solid, and soft tissue mass involving the
proximal epimetaphysis of the tibia and extending to the subarticular
cortex. a Preoperative scan. b Scan obtained 6 months postoperatively
showing a mild decrease in the size of the lesion with increased
sclerosis of the solid component. c Scan obtained 2.5 years
postoperatively showing a further decrease in the size of the mass
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ml to 42.17 ± 12.98 ng/ml after weekly treatment with
50,000 IU of vitamin D, but that pre- and posttreatment
unadjusted serum calcium remained stable in the high-
dose group [15].
We administered a 50,000-IU weekly dose of vitamin
D in our patient, and at her 4-month follow-up her
serum calcium levels had risen to 3.02 mmol/L. After
her 4-month follow-up, we reduced the dose to 5000 IU
weekly and her calcium levels returned to baseline. We
suggest that further trials be done to study the effect of
high-dose vitamin D in different patient populations,
and inclusion and exclusion criteria should be developed
to assess the candidates in whom high doses can safely
be administered without increasing the risk of hypercal-
cemia and/or hypercalciuria and renal stones.
The overall outcome of our less aggressive approach
relieved the patient of unnecessary anxiety regarding an
additional surgical intervention and its consequences.
Our patient was pleased with the cosmetic outcome and
the progress of her recovery.
The limitations in the management of this case were
due to lack of specific guidelines for management of
vitamin D deficiency in patients with features of both
PHPT and secondary vitamin D deficiency-induced hyper-
parathyroidism. In addition, we were unable to retrieve a
photograph of the patient from the initial presentation for
comparison in this case report. However, the main
strength of our management was in early referral and in-
volvement of multiple specialists in the appropriate care
of our patient. This multidisciplinary approach prevented
us from misdiagnosis of the tumor and from performing
deforming radical surgeries in the maxillofacial region.
Working in a specialist center and having a cooperative
patient also allowed us to carry out all necessary diagnos-
tic and therapeutic interventions without any delay. We
were able to follow our patient very closely with blood in-
vestigations of vitamin D, parathyroid hormone, calcium,
and phosphorous levels to determine the causation be-
tween high-dose vitamin D therapy and hypercalcemia.
Conclusions
On the basis of this case report, we stress the signifi-
cance of actively involving radiologists, endocrinolo-
gists, surgical oncologists, and maxillofacial surgeons
Fig. 5 Technetium Tc-99 m sestamibi parathyroid study showing increased activity in the soft tissue mass, approximately 13.0 mm in size and
lying behind the lower part of the right thyroid lobe
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in the management of this type of case. In addition, it
should be kept in mind that atypical age demographics and
tumor sites should not rule out brown tumor as a differen-
tial diagnosis. Last, the patient’s laboratory and radiological
investigations should always be supported by clinical im-
pression, and the psychological impact of the disease on
the patient should be one of the deciding factors for estab-
lishing the management plan, as it was for us.
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